Reverse transcriptase-based DNA vaccines against drug-resistant HIV-1 tested in a mouse model

Vaccine

Volumn 22, Issue 13-14, 2004, Pages 1810-1819

  Isaguliants, Maria G ^a,b   Zuber, Bartek ^a   Boberg, Andreas ^a   Sjöstrand, Dan ^a   Belikov, Sergey V ^b,c   Rollman, Erik ^a   Zuber, Anne Kjerrström ^a   Rechinsky, Vladimir O ^d   Rytting, Ann Sofie ^e   Källander, Clas F R ^e   Hinkula, Jorma ^a   Kochetkov, Sergey N ^d   Liu, Margaret ^f,g   Wahren, Britta ^a,g  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b D I IVANOVSKY INSTITUTE OF VIROLOGY   (Russian Federation)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^e Cavidi Tech AB   (Sweden)

^f TRANSGENE S A   (France)

^g KAROLINSKA INSTITUTE   (Sweden)

Author keywords

DNA immunization; Drug resistance mutations; HIV 1 reverse transcriptase

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; HLA A ANTIGEN; RNA DIRECTED DNA POLYMERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CODON; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; GENE EXPRESSION; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNIZATION; MOLECULAR CLONING; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; DRUG RESISTANCE, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FLUORESCENT ANTIBODY TECHNIQUE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HLA-A ANTIGENS; IMMUNOASSAY; IMMUNOBLOTTING; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; MUTATION; OOCYTES; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; VACCINES, DNA; XENOPUS LAEVIS;

EID: 11144356371     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.10.052     Document Type: Article

References (52)

1. Arts E.J., Wainberg M.A. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob. Agents Chemother. 40:1996;527-540.
2. De Clercq E. Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 8:1995;200-239.
3. De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Med. Res. Rev. 16:1996;125-157.
4. Esnouf R., Ren J., Ross C., Jones Y., Stammers D., Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 2:1995;303-308.
5. Havlir D.V., Eastman S., Gamst A., Richman D.D. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J. Virol. 70:1996;7894-7899.
6. Young B.S., Johnson M., Bahktiari D., Shugarts D., Young R.K., Allen M. et al. Resistance mutations in protease and reverse transcriptase genes of HIV-1 isolates from patients with combination antiretroviral therapy failure. J. Infect. Dis. 178:1998;1497-1501.
7. Hecht F.M., Grant R.M., Petropoulos C.J., Dillon B., Chesney M.A., Tian H.et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N. Engl. J. Med. 339:1998;307-311.
8. Iversen A.K., Shafer R.W., Wehrly K., Winters M.A., Mullins J.I., Chesebro B.et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1996;1086-1090.
9. Miller V., Larder B.A. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir. Ther. 6(Suppl. 3):2001;25-44.
10. Mayers D.L. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs. Am. J. Med. 102:1997;70-75.
11. Phillips A. Will the drugs still work? Transmission of resistant HIV. Nat. Med. 7(9):2001;993-994.
12. Letvin N.L. Progress in the development of an HIV-1 vaccine. Science. 280:1998;1875-1880.
13. Walker C.M., Moody D.J., Stites D.P., Levy J.A. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science. 234:1986;1563-1566.
14. Chouquet C., Autran B., Gomard E., Bouley J.M., Calvez V., Katlama C.et al. Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection. AIDS. 16(18):2002;2399-2407.
15. Barouch D.H., Kunstman J., Kuroda M.J., Schmitz J.E., Santra S., Peyerl F.W.et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature. 415(6869):2002;335-339.
16. Pantaleo G., Demarest J.F., Soudeyns H., Graziosi C., Denis F., Adelsberger J.W.et al. Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature. 370:1994;463-467.
17. Ogg G.S., Jin X., Bonhoeffer S., Dunbar P.R., Nowak M.A., Monard S.et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 279:1998;2103-2106.
18. Autran B., Hadida F., Haas G. Evolution and plasticity of CTL responses against HIV. Curr. Opin. Immunol. 8:1996;546-553.
19. Heintel T., Sester M., Rodriguez M.M., Krieg C., Sester U., Wagner R.et al. The fraction of perforin-expressing HIV-specific CD8 T cells is a marker for disease progression in HIV infection. AIDS. 16(11):2002;1497-1501.
20. Yang O.O. Will we be able to 'spot' an effective HIV-1 vaccine? Trends Immunol. 24(2):2003;67-72.
21. Schmitt M., Harrer E., Goldwich A., Bauerle M., Graedner I., Kalden J.R.et al. Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes. AIDS. 14:2000;653-658.
22. Samri A., Haas G., Duntze J., Bouley J.M., Calvez V., Katlama C.et al. Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for HIV-1-specific cytotoxic T cells. J. Virol. 74:2000;9306-9312.
23. Edgeworth R.L., San J.H., Rosenzweig J.A., Nguyen N.L., Boyer J.D., Ugen K.E. Vaccine development against HIV-1: current perspectives and future directions. Immunol. Res. 25(1):2002;53-74.
24. Hanke T., McMichael A.J., Mwau M., Wee E.G., Cebereg I., Patel S.et al. Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine. 20:2002;1995-1998.
25. Muthumani K., Kudchodkar S., Zhang D., Bagarazzi M.L., Kim J.J., Boyer J.D.et al. Issues for improving multiplasmid DNA vaccines for HIV-1. Vaccine. 20:2002;1999-2003.
26. Amara R.R., Robinson H.L. A new generation of HIV vaccines. Trends Mol. Med. 8:2002;489-495.
27. Isaguliants M.G., Petrakova N.V., Zuber B., Pokrovskaya K., Gizatullin R., Kostyak D.A.et al. DNA encoding enzymatically active HIV-1 reverse transcriptase, but not the inactive mutant, confers resistance to experimental HIV-1 challenge. Intervirology. 43:2000;288-293.
28. Isaguliants M.G., Gudima S.O., Ivanova O.V., Levi M., Hinkula J., Garaev M.M.et al. Immunogenic properties of reverse transcriptase of HIV type 1 assessed by DNA and protein immunization of rabbits. AIDS Res. Hum. Retroviruses. 16(13):2000;1269-1280.
29. Zuber B., Mäkitalo B., Kjerrström Zuber A., Wahren B. A novel potent strategy for induction of immunity to HIV-1 reverse transcriptase in primates. AIDS. 16:2002;1839-1840.
30. Huang Y., Kong W.P., Nabel G.J. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J. Virol. 75:2001;4947-4951.
31. Casimiro D.R., Tang A., Perry H.C., Long R.S., Chen M., Heidecker G.J.et al. Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene. J. Virol. 76(1):2002;185-194.
32. Zuber B., Böttiger D., Benthin R., ten Haaft P., Heeney J., Wahren B.et al. An in vivo model for HIV resistance development. AIDS Res. Hum. Retrovirus. 17:2001;631-635.
33. Takahashi H., Nakagawa Y., Yokomuro K., Berzofsky J.A. Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int. Immunol. 5:1993;849-857.
34. Panina-Bordignon P., Tan A., Termijtelen A., Demotz S., Corradin G., Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:1989;s2237-s2242.
35. Stemmer W.P., Crameri A., Ha K.D., Brennan T.M., Heyneker H.L. Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides. Gene. 164:1995;49-53.
36. Lund L.H., Andersson K., Zuber B., Karlsson A., Engstrom G., Hinkula J. et al. Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system. Cancer Gene Ther. 10(5):2003;365-376.
37. Rytting A.S., Akerblom L., Albert J., Unge T., Bjorling E., Al-Khalili L.et al. Monoclonal antibodies to native HIV type 1 reverse transcriptase and their interaction with enzymes from different subtypes. AIDS Res. Hum. Retroviruses. 16:2000;1281-1294.
38. Robinett C.C., Dunaway M. Modeling transcriptional regulation using microinjection into xenopus oocytes. Methods Enzymol. 17:1999;151-160.
39. Pokholok D.K., Gudima S.O., Esipov D.S., Dobrynin V.N., Memelova L.V., Rechinskii V.O.et al. Studies of the resistance of the human immunodeficiency virus to azidothymidine. I. Kinetic studies of the interaction between reverse transcriptase and a series of its mutant forms with substrates and azidothymidine-5′-trisphosphate. Biokhimiia. 59(5):1994;739-747.
40. Vitiello A.D., Marchesini J., Furze J., Sherman L.A., Chesnut R.W. Analysis of the HLA-restricted influenza specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173:1991;1007-1015.
41. Charo J., Sundback M., Geluk A., Ottenhoff T., Kiessling R. DNA immunization of HLA transgenic mice with a plasmid expressing mycobacterial heat shock protein 65 results in HLA class I- and II-restricted T cell responses that can be augmented by cytokines. Hum. Gene Ther. 12(14):2001;1797-1804.
42. Ljungberg K., Rollman E., Eriksson L., Hinkula J., Wahren B. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology. 302(1):2002;44-57.
43. Jonckeere H., de Clercq E. The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med. Res. Rev. 20:2000;129-154.
44. Mellors J.W., Bazmi H.Z., Scinazi R.F., Roy B.M., Hsiou Y., Arnold E.et al. Novel mutations in reverse transcriptase of HIV type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob. Agents Chemother. 39:1995;1087-1092.
45. Livingston B.D., Newman M., Crimi C., McKinney D., Chesnut R., Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine. 19:2001;4652-4660.
46. Shafer R.W., Hertogs K., Zolopa A.R., Warford A., Bloor S., Betts B.J.et al. High degree of interlaboratory reproducibility of HIV-1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J. Clin. Microbiol. 39:2001;1522-1529.
47. Hertogs K, Bloor S, De Vroey V, van der Eynde C, Dehertogh P, van Cauwenberge, et al. A novel HIV-1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother 2000;44:568-73.
48. Cazeaux N., Bennasser Y., Vidal P.L., Li Z., Paulin D., Bahraoui E. Comparative study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter. Vaccine. 20:2002;3322-3331.
49. Arion D., Borkow G., Kaushik N., McCormick S., Parniak M.A. Phenotypic mechanism of HIV-1 resistance to AZT: increased DNA polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry. 37:1998;15908-15917.
50. Gao H.Q., Boyer P.L., Arnold E., Hughes S.H. Effects of mutations in the polymerase domain on the polymerase, RNase H and strand transfer activities of HIV-1 reverse transcriptase. J. Mol. Biol. 277:1998;559-572.
51. Isaguliants MG, Belikov SV, Starodubova ES, Gizatullin RZ, Rollman E, Zuber B, et al. Mutations conferring drug resistance affect eukaryotic expression of HIV-1 reverse transcriptase. AIDS Res & Hum Retrovir 2004;20(2):191-201.
52. Whitton J.L., Sheng N., Oldstone M.B., McKee T.A. A "string-of- beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J. Virol. 67:1993;348-352.